


PHARMACEUTICAL 2020

Skye Bioscience Inc. Rank 12 of 362





PHARMACEUTICAL 2020



Skye Bioscience Inc. Rank 12 of 362

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 1,823% points. The greatest weakness of Skye Bioscience Inc. is the variable Revenues, reducing the Economic Capital Ratio by 460% points.

The company's Economic Capital Ratio, given in the ranking table, is 283%, being 586% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,995
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	971
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1.6
Other Liabilities	478
Other Net Income	7,686
Property and Equipment	2.0
Research and Development	2,238
Revenues	0
Selling, General and Administrative Expense	4,395

Output Variable	Value in 1000 USD
Assets	1,997
Liabilities	1,449
Expenses	6,634
Stockholders Equity	548
Net Income	1,052
Comprehensive Net Income	1,052
Economic Capital Ratio	283%